Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. develops sublingual delivery technology designed to deliver drugs and other bioactive substances through rapid absorption under the tongue. Company news commonly covers its drug-delivery platform, applications across active pharmaceutical ingredients, therapeutics, nutraceuticals and supplements, and clinical or regulatory disclosures tied to its development activities.
Updates also include the company’s wholly owned Buzz Bomb Caffeine Company, which markets BUZZ BOMB™ caffeine in single-serving dry powder stick packs for sublingual use. Recurring corporate developments include retail distribution and sales agreements, operating and financial results, shareholder voting matters, governance updates, Nasdaq listing compliance and capital-structure actions such as reverse stock split approvals.
Aspire Biopharma (NASDAQ:ASBP) announced delivery of two million units of its flagship caffeine supplement BUZZ BOMB™ on January 22, 2026, and strategic inventory of 100,000 20-packs now available to meet demand. The rollout includes a modernized brand identity, redesigned high-impact packaging, an emphasis on 50mg precise dosing and near-instant sublingual absorption, and a new e-commerce storefront. Aspire plans an aggressive growth push via expanded digital marketing, influencer partnerships, DTC optimization, and evaluation of retail and wholesale channels to scale the consumer business.
Aspire Biopharma (NASDAQ:ASBP) announced a comprehensive brand redesign for its flagship caffeine product, BUZZ BOMB™ on January 21, 2026. The initiative includes a new logo, a mobile‑optimized e-commerce website at https://buzzbombcaffeine.com, and redesigned packaging with a vibrant aesthetic to emphasize rapid, sustained focus and sublingual delivery.
The website offers a streamlined shopping experience, product information, promotions, and educational content. Management says the redesign aims to improve customer engagement, showcase the product's capabilities, and position BUZZ BOMB for growth.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a first-ever sublingual powder formulation of alprazolam, aiming to improve bioavailability and accelerate onset versus oral tablets. The filing covers a sublingual delivery system designed to absorb alprazolam under the tongue to bypass first-pass metabolism and potentially shorten onset from about 30 minutes to minutes.
The company said it plans a Phase 1 clinical trial in mid-2026 and intends to pursue commercialization via the FDA 505(b)(2) pathway. Aspire framed this program as part of a broader pipeline of reformulated approved therapeutics targeting patients needing rapid relief or who have difficulty swallowing.
Aspire Biopharma (NASDAQ:ASBP) announced a 1-for-40 reverse stock split of its common stock effective 12:01 a.m. ET on January 16, 2026, with split-adjusted trading beginning at market open on January 16, 2026. The split reduces outstanding shares from approximately 158.8 million to approximately 4.0 million (fractions excluded). The board approved the 1-for-40 ratio after stockholder authorization for a 1-for-5 to 1-for-40 range at the November 4, 2025 meeting. The company will file a Certificate of Amendment on January 15, 2026 and will continue trading under ticker ASBP with a new CUSIP 738920 206. The reverse split is being implemented to help ensure compliance with The Nasdaq Capital Market's minimum bid price requirement. Fractional shares will be rounded up to the nearest whole share at the participant level; no fractional shares will be issued.
Aspire Biopharma (Nasdaq: ASBP) completed a Type B pre-IND meeting with the FDA on January 7, 2026, receiving written feedback that supports a Section 505(b)(2) NDA filing in H2 2026 after a planned clinical trial.
The company will run a multicenter crossover study in 32 healthy volunteers comparing OTASA 162 mg sublingual powder vs. two chewed 81 mg aspirin tablets, measuring serum thromboxane B2 (TxB2) inhibition. Pilot data showed faster ASA absorption, TxB2 inhibition within two minutes, and no reported adverse events. Management said the FDA alignment de-risks the regulatory path and could support a breakthrough therapy request.
Aspire Biopharma (Nasdaq: ASBP) announced on December 18, 2025 that elite ultra-runner and Ironman champion Ashley Paulson is joining as global Brand Ambassador for BUZZ BOMB®, Aspire's sublingual caffeine product.
Paulson's credentials include 130+ marathons, 25+ Ironman-distance triathlons, multiple ultra triathlons, two 281.2-mile events, 6+ 100-mile races, Badwater 135 Women’s Champion (2022) and Overall Champion (2023). Aspire says Paulson will lead digital campaigns, exclusive training content, and represent BUZZ BOMB at major endurance events in 2026. BUZZ BOMB is positioned as near-instant sublingual caffeine for rapid energy without digestive upset. Paulson's social reach is listed as ~174,000 Instagram, 23,000 TikTok, and 12,000 Facebook followers.
Aspire Biopharma (Nasdaq: ASBP) received a notice from the Nasdaq Hearings Panel granting an extension to continue its Nasdaq listing, subject to conditions after the Company's transfer to the Nasdaq Capital Market.
The company will transfer its common stock listing effective at market open on December 15, 2025, retain the symbol ASBP, and must demonstrate compliance with the Bid Price Rule (Rule 5550(a)(2)) by January 30, 2026 and the Equity Rule (Rule 5550(b)(1)) by February 17, 2026. Management said it expects to cure the bid-price and market-value deficiencies and is working to recapitalize the balance sheet.
Aspire Biopharma (Nasdaq:ASBP) provided a Q3 2025 business update highlighting clinical, regulatory, IP, commercial, and manufacturing progress.
Key disclosed developments: the company reported positive final bioavailability data for its sublingual high-dose aspirin showing platelet inhibition in under 2 minutes (about 4–5x faster than chewed aspirin); filed an omnibus patent application covering its sublingual delivery platform; received a positive FDA response to its Pre-IND request with written feedback due by Jan 2, 2026; and raised commercial capacity with an initial production order of 2 million servings of BUZZ BOMB™ caffeine ahead of a consumer e-commerce launch. The company targets an NDA submission in H1 2026 for the sublingual aspirin program.
Aspire Biopharma (NASDAQ:ASBP) said it submitted a Pre-IND meeting request and briefing package on November 3, 2025 to the U.S. FDA for its lead product: a fast-acting, high-dose sublingual aspirin for suspected acute myocardial infarction (AMI).
Company-reported trial results claim the formulation begins to inhibit platelet aggregation in under two minutes, acting 4–5× faster than chewed aspirin, with higher mean plasma ASA and reduced serum TxB2 within two minutes; the product was described as safe and well-tolerated. Aspire intends to pursue a 505(b)(2) regulatory pathway toward a future NDA.
Aspire Biopharma (NASDAQ:ASBP) announced the November 4, 2025 hire of Mark J. Jaroszeski, PhD to its scientific team. Dr. Jaroszeski is a tenured professor of Medical Engineering at the University of South Florida with a PhD in Engineering Science and a long record in DNA and drug delivery, including early in vivo electroporation work, 34 U.S. patents, and leadership roles in academic and startup research.
The company said his expertise will support development and optimization of Aspire's patent-pending sublingual delivery technology and help extend the platform across its pipeline of generic medicines.